ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2015

Feb 18, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: INOTEK PHARMACEUTICALS CORP (ITEK)
CIK: 0001281895
Period of Report: 2015-02-17

Reporting Person: Baumgartner Rudolph (See Remarks)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series X Convertible Preferred Stock	$		Common Stock (125642)		Direct
Stock Options (right to buy)	$40.578	2017-06-03	Common Stock (2170)		Direct
Stock Options (right to buy)	$40.578	2018-03-20	Common Stock (197)		Direct
Stock Options (right to buy)	$4.342	2024-08-28	Common Stock (199248)		Direct

Footnotes

F1: The Series X Convertible Preferred Stock ("Series X Preferred") is convertible at any time at the holder's election and has no expiration date. All shares of Series X Preferred, including all accrued and unpaid dividends thereon, will be automatically converted on a 4.05783-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering. The number of shares of Common Stock as shown in column 3 is based on a conversion of 509,837 shares of Series X Preferred.

F2: These options are fully vested.

F3: These options shall vest 25% on August 29, 2015, and the remainder shall vest in equal monthly installments thereafter over 36 months, provided, that no portion of this stock option shall become vested and exercisable until the consummation of the issuer's initial public offering.